2016
DOI: 10.1007/s00125-015-3839-6
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice

Abstract: Aims/hypothesis The mammalian target of rapamycin complex 1 (mTORC1)/p70 ribosomal S6 kinase (S6K)1 pathway is overactivated in obesity, leading to inhibition of phosphoinositide 3-kinase (PI3K)/Akt signalling and insulin resistance. However, chronic mTORC1 inhibition by rapamycin impairs glucose homeostasis because of robust induction of liver gluconeogenesis. Here, we compared the effect of rapamycin with that of the selective S6K1 inhibitor, PF-4708671, on glucose metabolism in vitro and in vivo. Methods We… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

5
47
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 48 publications
(52 citation statements)
references
References 50 publications
5
47
0
Order By: Relevance
“…The phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/Akt) signaling pathway was suppressed in diabetes[53, 54]. Our results showed that TLR4 interfering suppressed the PI3K/Akt pathway, mitigating the abnormal mesangial cell proliferation.…”
Section: Discussionmentioning
confidence: 65%
“…The phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B (PI3K/Akt) signaling pathway was suppressed in diabetes[53, 54]. Our results showed that TLR4 interfering suppressed the PI3K/Akt pathway, mitigating the abnormal mesangial cell proliferation.…”
Section: Discussionmentioning
confidence: 65%
“…S6K1 has been recently pursued as a molecular target for sensitizing the insulin receptor and for controlling hyperglycemia . Shum et al .…”
Section: Discussionmentioning
confidence: 99%
“…S6K1 has been recently pursued as a molecular target for sensitizing the insulin receptor and for controlling hyperglycemia. [29] Shum et al [29] reported that PF-4708671, a specific inhibitor of S6K1, sensitizes the insulin receptor and enhances glucose uptake. We recently identified S6K1 as a molecular target of A77 1726, the active metabolite of anti-rheumatoid arthritis (RA) drug leflunomide.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Thus, PF-4708671 had been used in studies determining the role of S6K1 and mTORC1 in physiological and pathological conditions [25][26][27][28]. The inhibitory effect of PF-4708671 on S6K was confirmed by measuring the phosphorylation of S6, which is a downstream target of S6K, in previous studies [22,[25][26][27][28]. Therefore, we similarly examined effects of PF-4708671 on pS6 levels in retinas.…”
Section: Discussionmentioning
confidence: 92%